RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
ESMO TAT 2023, 6-8 March, Paris 🡕 Abstract ⤓ Poster RS-0139 is the lead candidate of RS Research, a clinical-stage biotechnology start-up harvesting the superior therapeutic index that PDC Therapeutics’ SagittaTM platforms are ready to offer. Presenters Gulsah Nomak Citation Annals of Oncology (2023) 8 (1suppl_2): 100898-100898. 10.1016/esmoop/esmoop100898 Authors G. Nomak1, M. Karacivi2, S. Kutlu Ozkaya2, […]
